Intelligence Β· Clinical Pipeline

Vertex Pharmaceuticals (Australia) Pipeline

All ClinicalTrials.gov programs at Vertex Pharmaceuticals (Australia) β€” phase, modality, and trial IDs.

Programs
159

Quick answer

Vertex Pharmaceuticals (Australia) has 159 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. VX-702

    Vertex Pharmaceuticals (Australia) Pty.

    Rheumatoid Arthritis

    phase 2 small molecule completed

    2 trials
  2. VX-765

    Vertex Pharmaceuticals (Australia) Pty.

    Psoriasis

    phase 2 small molecule completed

    1 trial
  3. VX-765

    Vertex Pharmaceuticals (Australia) Pty.

    Partial Epilepsy

    phase 2 small molecule completed

    1 trial
  4. VX-765 Part A

    Vertex Pharmaceuticals (Australia) Pty.

    Epilepsy

    phase 2 small molecule terminated

    1 trial
  5. VX-770

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    3 trials
  6. VX-787

    Vertex Pharmaceuticals (Australia) Pty.

    Influenza Virus

    phase 2 small molecule completed

    1 trial
  7. VX-814

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule terminated

    1 trial
  8. VX-864

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha-1 Antitrypsin Deficiency

    phase 2 small molecule terminated

    1 trial
  9. VX-864

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha1-Antitrypsin Deficiency

    phase 2 small molecule completed

    1 trial
  10. VX-950

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    2 trials
  11. VX-993

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathic Pain

    phase 2 small molecule active

    1 trial
  12. VX-993

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 2 small molecule completed

    1 trial
  13. biricodar dicitrate

    Vertex Pharmaceuticals (Australia) Pty.

    Lung Cancer

    phase 2 small molecule terminated

    1 trial
  14. telaprevir

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C Virus Infection

    phase 2 small molecule terminated

    1 trial
  15. telaprevir or matching placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial
  16. 14C-VX-993

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    1 trial
  17. ALS-002158

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 1 small molecule terminated

    1 trial
  18. ALS-002200

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 1 small molecule completed

    1 trial
  19. AVN-944 capsules for oral administration

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Leukemia

    phase 1 small molecule completed

    1 trial
  20. IXP

    Vertex Pharmaceuticals (Australia) Pty.

    Focal Segmental Glomerulosclerosis (FSGS)

    phase 1 small molecule completed

    1 trial
  21. IXP

    Vertex Pharmaceuticals (Australia) Pty.

    Renal Impairment

    phase 1 small molecule completed

    1 trial
  22. MP-424 (Telaprevir)

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial
  23. MP-424(H), PEG-IFN-a-2b, RBV

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial
  24. PegInterferon

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial
  25. Placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    1 trial
  26. Povetacicept

    Vertex Pharmaceuticals (Australia) Pty.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  27. Prednisone

    Vertex Pharmaceuticals (Australia) Pty.

    Drug Interactions

    phase 1 small molecule completed

    1 trial
  28. SUZ

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    1 trial
  29. Telaprevir

    Vertex Pharmaceuticals (Australia) Pty.

    Healthy Participants

    phase 1 small molecule completed

    1 trial
  30. Telaprevir; Moxifloxacin; Placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial
  31. Treatment sequence AB

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial
  32. VCH 916

    Vertex Pharmaceuticals (Australia) Pty.

    HCV Infection

    phase 1 small molecule completed

    1 trial
  33. VCH-222

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial
  34. VX-118

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 1 small molecule completed

    1 trial
  35. VX-147

    Vertex Pharmaceuticals (Australia) Pty.

    Focal Segmental Glomerulosclerosis (FSGS)

    phase 1 small molecule completed

    1 trial
  36. VX-150

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    1 trial
  37. VX-272

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 1 small molecule active

    1 trial
  38. VX-433

    Vertex Pharmaceuticals (Australia) Pty.

    Narcolepsy Type 1 (NT1)

    phase 1 small molecule active

    1 trial
  39. VX-440

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 1 small molecule completed

    1 trial
  40. VX-509

    Vertex Pharmaceuticals (Australia) Pty.

    Healthy

    phase 1 small molecule completed

    1 trial
  41. VX-548

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    7 trials
  42. VX-581

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 1 small molecule active

    1 trial
  43. VX-634

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha 1-Antitrypsin Deficiency

    phase 1 small molecule completed

    1 trial
  44. VX-668

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha-1 Antitrypsin Deficiency

    phase 1 small molecule completed

    1 trial
  45. VX-708

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 1 small molecule completed

    1 trial
  46. VX-708

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    1 trial
  47. VX-770

    Vertex Pharmaceuticals (Australia) Pty.

    In Development for Cystic Fibrosis

    phase 1 small molecule completed

    2 trials
  48. VX-828

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 1 small molecule active

    2 trials

Frequently asked questions

How many pipeline programs does Vertex Pharmaceuticals (Australia) have?

159 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources Β· All pipeline programs